

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	8105581
<b>Application Number:</b>	10600266
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7488
<b>Title of Invention:</b>	MEDICINAL COMPOSITIONS CONTAINING ASPIRIN
<b>First Named Inventor/Applicant Name:</b>	Fumitoshi Asai
<b>Customer Number:</b>	65989
<b>Filer:</b>	Wan Chieh Lee
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	17620-105003
<b>Receipt Date:</b>	28-JUL-2010
<b>Filing Date:</b>	20-JUN-2003
<b>Time Stamp:</b>	13:50:56
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$810
RAM confirmation Number	101
Deposit Account	503732
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	RCE.pdf	799731	no	1
			c150bc16762b8941ccedf5db7edfc125fca93fa		
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
2	Transmittal Letter	IDSltr.pdf	1596592	no	3
			581566d77b6d6e118b266d8f97e11b7b17ce44a0		
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Filed (SB/08)	SB08.pdf	154656	no	5
			6a982cd1871ee771715d81867807316dc3f643f6		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
4	NPL Documents	AinoLepantalo.pdf	10690623	no	115
			1906b043412167e7ef780c23160272583a05b		
Warnings:					
Information:					
5	NPL Documents	Akyuz1999.pdf	1342904	no	5
			90d7408a806732a7b49c86a6a3070e11582b		
Warnings:					
Information:					
6	NPL Documents	Alexander.pdf	853697	no	5
			dbf9407cc9fbd509c218071dc2d3ac99f515dc9797		
Warnings:					
Information:					
7	NPL Documents	Antman.pdf	854519	no	6
			c22e1baad2f4b0dd0adb799918f5f80-b0c49d12a		
Warnings:					
Information:					

8	NPL Documents	Aspirin_MeReC.pdf	294057 bc2c3e8f78c6530829da219e320cde470e954	no	2
Warnings:					
Information:					
9	NPL Documents	Chap52HeartDiseaseBook.pdf	389647 73e4d8d2298a0a0ac54b6594dc338f97459638	no	2
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
10	NPL Documents	Clagette.pdf	9836606 249248032ca711205c402075911b77e64949eb1	no	32
Warnings:					
Information:					
11	NPL Documents	Clarke.pdf	1358489 c88147alc0b02c20b7b1497334db60654d61cda1	no	7
Warnings:					
Information:					
12	NPL Documents	Collaborative.pdf	2358304 a753dbbf7056c6d289bdf11e69b847a1fb966	no	16
Warnings:					
Information:					
13	NPL Documents	CURETrial2000.pdf	454400 a891337ac3d0138f7c5b79823166cb70955e956	no	9
Warnings:					
Information:					
14	NPL Documents	CURETrial2001.pdf	8547461 1c39c5ad7ccaf8bc07111e0bd892ac2c327b95ae	no	13
Warnings:					
Information:					
15	NPL Documents	Erlinge.pdf	1309481 9874d1842a2af9dd1028a895928475dc913ce7f1	no	10
Warnings:					
Information:					
16	NPL Documents	Farrell1999.pdf	144566 3c467383d1e0b006b1c54a37a9a39145b1c0887	no	5

Warnings:					
Information:					
17	NPL Documents	Fayer.pdf	1459353 2e1006d8b6c6d8d6d8b7ba79b4511e091975547a4b	no	8
Warnings:					
Information:					
18	NPL Documents	Ferguson.pdf	1193072 a9d9df165720dc4d79a117034d79ccc50b4e78a	no	8
Warnings:					
Information:					
19	NPL Documents	Henke2008.pdf	35838 822946f1b5591938d00138167b2f8b24c4553c7	no	2
Warnings:					
Information:					
20	NPL Documents	Jaremo.pdf	657906 6d8eba09862b15823c7bd917212916c61022d802	no	6
Warnings:					
Information:					
21	NPL Documents	Lau.pdf	138590 c1ed8dc058c7dbcc5ee9098032466c64b16cc294db	no	2
Warnings:					
Information:					
22	NPL Documents	Lipton.pdf	694987 15a0f8cc479df1244de1276cdcf04c66803385ee	no	11
Warnings:					
Information:					
23	NPL Documents	MurphyHeart2008.pdf	1352801 #f52ccc492a20b49375881d0c050c7e5b76255	no	7
Warnings:					
Information:					
24	NPL Documents	Payne2007.pdf	1374537 2561801bf45b397e428bc59f63c65104a4596d78	no	8
Warnings:					
Information:					
25	NPL Documents	Payne2008.pdf	1209479 13b4da3f6bd1ff3f8b26427d5ccc3a2c69c5c3f	no	7

Warnings:					
Information:					
26	NPL Documents	J_Chem_Abst282.pdf	36435 8f94530a72e0488f99ede1e025519a2b7ecfa045	no	1
Warnings:					
Information:					
27	NPL Documents	Lovenox2000label.pdf	12599295 ff6ebc1b17db6f95b4f04f02a12a43cbe0f180c	no	24
Warnings:					
Information:					
28	NPL Documents	FDASlideNo26.pdf	33933 3bee413c3a278d79f1d30962c6b81a01221071	no	1
Warnings:					
Information:					
29	NPL Documents	Reinhart.pdf	1655218 d41be0d8640104130c713e4021122a0302ba971	no	11
Warnings:					
Information:					
30	NPL Documents	ResponsetoEPOppositon3_26_10.pdf	2189150 095d125eafed1412aa506521ce82be9c523b2e5	no	36
Warnings:					
Information:					
31	NPL Documents	ResponseJune92010.pdf	306825 6aa1182b6f8b0070c3188a1161a12b15f0ebd0e	no	10
Warnings:					
Information:					
32	NPL Documents	Reuters.pdf	135796 2b19c0ab15fae1dbaf61fb1d0ba766ae03ba09	no	2
Warnings:					
Information:					
33	NPL Documents	Thebault.pdf	947155 7ae9988802c34486c5baf13e6c9c3b7f224f09cd	no	6
Warnings:					
Information:					
34	NPL Documents	Uzun.pdf	3157420 130f020006b6f4bb6cd385ede0fbc7f931058b3e	no	4

Warnings:

Information:					
35	NPL Documents	Wallentin.pdf	2868720	no	10
			bc4997acc261440b36133bf5d0b39f6f110462		
Warnings:					
Information:					
36	NPL Documents	WiviottCirculation2008.pdf	2047659	no	11
			5e631598159c26c70031dd1813146b3214e6f5a6c		
Warnings:					
Information:					
37	NPL Documents	Wiviott2008.pdf	2979926	no	11
			d190af3129d1dc3de361c40b5ccc22d6d8f7f9e514		
Warnings:					
Information:					
38	NPL Documents	WiviottCirculation2007.pdf	1921856	no	10
			b3d14e27796c19c349556505714c8ac2acc23e48		
Warnings:					
Information:					
39	NPL Documents	WiviottNEJNov2007.pdf	3014151	no	15
			7ba54db9d80a6c4556a43e17c261711c724494b		
Warnings:					
Information:					
40	NPL Documents	WiviottCirculation2005.pdf	1539652	no	8
			c79c77bee1d9ade8b598ee458fa78b605d1369		
Warnings:					
Information:					
41	NPL Documents	Worrall2000.pdf	5882387	no	6
			6aaf00bc081d4512d299c95d212b3b101c26c3819		
Warnings:					
Information:					
42	NPL Documents	Yende2001.pdf	124512	no	5
			1e63e78910c9d199903d4116d2a2ac1eaf5b4db		
Warnings:					
Information:					
43	Fee Worksheet (PTO-875)	fee-info.pdf	30156	no	2
			7fa305508a67ceda9c30c7a0ff7c4d01173f9c37c		

**Warnings:****Information:****Total Files Size (in bytes):**

90572542

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.